Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants
Movement Disorders · 2023-12 · 38 (12) · 2155-2162
DOI: 10.1002/mds.29647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 02.11.2023. Verfasst von Gian D Pal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Movement Disorders, Department of Neurology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Cognition Disorders, Deep Brain Stimulation, Parkinson Disease, Subthalamic Nucleus. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCD NIH HHS, NICHD NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Genetic subtyping of patients with Parkinson's disease (PD) may assist in predicting the cognitive and motor outcomes of subthalamic deep brain stimulation (STN‐DBS). Practical questions were recently raised with the emergence of new data regarding suboptimal cognitive outcomes after STN‐DBS in individuals with PD associated with pathogenic variants in glucocerebrosidase gene ( GBA1 ‐PD). However, a variety of gaps and controversies remain. (1) Does STN‐DBS truly accelerate cognitive deterioration in GBA1 ‐PD? If so, what is the clinical significance of this acceleration? (2) How should the overall risk‐to‐benefit ratio of STN‐DBS in GBA1 ‐PD be established? (3) If STN‐DBS has a negative effect on cognition in GBA1 ‐PD, how can this effect be minimized? (4) Should PD patients be genetically tested before STN‐DBS? (5) How should GBA1 ‐PD patients considering STN‐DBS be counseled? We aim to summarize the currently available relevant data and detail the gaps and controversies that exist pertaining to these questions. In the absence of evidence‐based data, all authors strongly agree that clinicians should not categorically deny DBS to PD patients based solely on genotype ( GBA1 status). We suggest that PD patients considering DBS may be offered genetic testing for GBA1 , where available and feasible, so the potential risks and benefits of STN‐DBS can be properly weighed by both the patient and clinician. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Movement Disorders, Department of Neurology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
- Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, Illinois, USA.
- Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Faculty of Medicine, The Hebrew University and Hadassah, Jerusalem, Israel.
- Department of Neurosurgery, Hadassah Medical Center, Jerusalem, Israel.
- Department of Medical Neurobiology, Institute of Medical Research Israel-Canada (IMRIC), The Hebrew University-Hadassah Medical School, Jerusalem, Israel.
ORCID-Profile: Gian D Pal, David Arkadir
Förderung
- NIDCD NIH HHS
- NICHD NIH HHS
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Pal, G. D., Corcos, D. M., Metman, L. V., Israel, Z., Bergman, H., & Arkadir, D. (2023). Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants. Movement Disorders, 38(12), 2155-2162. https://doi.org/10.1002/mds.29647
Vancouver
Pal GD, Corcos DM, Metman LV, Israel Z, Bergman H, Arkadir D. Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants. Movement Disorders. 2023;38(12):2155-2162. doi:10.1002/mds.29647
BibTeX
@article{Pal2023,
author = {Pal, Gian D and Corcos, Daniel M and Metman, Leo Verhagen and Israel, Zvi and Bergman, Hagai and Arkadir, David},
title = {Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants},
journal = {Movement Disorders},
year = {2023},
volume = {38},
number = {12},
pages = {2155--2162},
doi = {10.1002/mds.29647}
}
EUVIMED